{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:20:27Z","timestamp":1783527627038,"version":"3.55.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    ADP-ribosylation is a reversible post-translational modification regulated by poly(ADP-ribose) polymerases (PARPs), a family of enzymes involved in DNA repair, transcriptional regulation, and immune responses. Among the 17 known PARP family members, PARP1 is the most extensively studied in autoimmune rheumatic diseases (ARDs). Although increasing evidence implicates PARP1 in ARD pathogenesis, its potential diagnostic and therapeutic relevance has not been systematically synthesised. This systematic literature review (SLR) aimed to evaluate the role of PARP1 in the pathogenesis, diagnosis and treatment of ARDs. MEDLINE and Embase databases were searched on 6th May 2026 using MeSH keywords for systemic ARDs, PARP1 and PARP inhibitors. Studies involving adult ARD patients and relevant animal models were included. Of 3564 records identified (post-deduplication), 41 studies were included. Seventeen studies included human ARD cohorts and nine used murine models recapitulating specific ARDs. Most studies focused on systemic lupus erythematosus (SLE;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918), rheumatoid arthritis (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200914), and systemic sclerosis (SSc;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20097). Across experimental models, inhibition or genetic disruption of PARP1 frequently attenuated inflammatory responses, reducing pro-inflammatory mediator expression, oxidative stress, and tissue damage. However, PARP1 also demonstrated context-dependent regulatory effects in immune signalling pathways. In SLE and SSc, reduced PARP1 activity and impaired DNA repair capacity were reported. Genetic association studies produced heterogeneous findings, while several studies identified PARP1-related autoantibodies or activity changes as potential diagnostic biomarkers, particularly in SLE. Overall, our SLR highlights PARP1 as an important regulator of immune pathways in ARDs, with potential relevance for future diagnostic and therapeutic strategies. PROSPERO: CRD420251000954.\n                  <\/jats:p>","DOI":"10.1007\/s00296-026-06187-0","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:57:35Z","timestamp":1780984655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PARP1 as a novel therapeutic and diagnostic tool in autoimmune rheumatic diseases: a systematic literature review"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-7955","authenticated-orcid":false,"given":"Malini","family":"Dey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6858-4338","authenticated-orcid":false,"given":"Mrinalini","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"6187_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.dnarep.2014.05.003","volume":"23","author":"D Perina","year":"2014","unstructured":"Perina D, Miko\u010d A, Ahel J, \u0106etkovi\u0107 H, \u017daja R, Ahel I (2014) Distribution of protein poly(ADP-ribosyl)ation systems across all domains of life. DNA Repair 23:4\u201316. https:\/\/doi.org\/10.1016\/j.dnarep.2014.05.003","journal-title":"DNA Repair"},{"issue":"8","key":"6187_CR2","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/bies.20085","volume":"26","author":"JC Am\u00e9","year":"2004","unstructured":"Am\u00e9 JC, Spenlehauer C, de Murcia G (2004) The PARP superfamily. Bioessays 26(8):882\u201393. https:\/\/doi.org\/10.1002\/bies.20085","journal-title":"Bioessays"},{"issue":"1","key":"6187_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/imm.13332","volume":"164","author":"MM Rosado","year":"2021","unstructured":"Rosado MM, Pioli C (2021) ADP-ribosylation in evasion, promotion and exacerbation of immune responses. Immunology 164(1):15\u201330. https:\/\/doi.org\/10.1111\/imm.13332","journal-title":"Immunology"},{"issue":"1","key":"6187_CR4","doi-asserted-by":"publisher","first-page":"10.1128\/mmbr.00","DOI":"10.1128\/mmbr.00038-18","volume":"83","author":"N Brady Pamlea","year":"2018","unstructured":"Brady Pamlea N, Goel A, Johnson Margaret A (2018) Poly(ADP-Ribose) polymerases in host-pathogen interactions, inflammation, and immunity. Microbiol Mol Biol Rev 83(1):10.1128\/mmbr.00038-18. https:\/\/doi.org\/10.1128\/mmbr.00038-18","journal-title":"Microbiol Mol Biol Rev"},{"issue":"10","key":"6187_CR5","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","volume":"21","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Gravallese EM (2021) Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol 21(10):680\u2013686. https:\/\/doi.org\/10.1038\/s41577-021-00603-1","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"6187_CR6","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm.3260","volume":"19","author":"G Schett","year":"2013","unstructured":"Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF (2013) How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 19(7):822\u20134. https:\/\/doi.org\/10.1038\/nm.3260","journal-title":"Nat Med"},{"issue":"9","key":"6187_CR7","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"6187_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103648","volume":"23","author":"L Arnaud","year":"2024","unstructured":"Arnaud L, Chasset F, Martin T (2024) Immunopathogenesis of systemic lupus erythematosus: an update. Autoimmun Rev 23(10):103648. https:\/\/doi.org\/10.1016\/j.autrev.2024.103648","journal-title":"Autoimmun Rev"},{"issue":"12","key":"6187_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41584-022-00864-7","volume":"18","author":"D Fang","year":"2022","unstructured":"Fang D, Chen B, Lescoat A, Khanna D, Mu R (2022) Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis. Nat Rev Rheumatol 18(12):683\u2013693. https:\/\/doi.org\/10.1038\/s41584-022-00864-7","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"6187_CR10","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/rheumatology\/keac584","volume":"62","author":"M Dey","year":"2023","unstructured":"Dey M, Nagy G, Nikiphorou E (2023) Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? Rheumatology (Oxford) 62(5):1773\u20131779. https:\/\/doi.org\/10.1093\/rheumatology\/keac584","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"6187_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/acr.24398","volume":"73","author":"B Dietz","year":"2021","unstructured":"Dietz B et al (2021) Major depression and adverse patient-reported outcomes in Systemic Lupus Erythematosus: results from a prospective longitudinal cohort. Arthritis Care Res (Hoboken) 73(1):48\u201354. https:\/\/doi.org\/10.1002\/acr.24398","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"6187_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3899\/jrheum.211135","volume":"49","author":"R Kallas","year":"2022","unstructured":"Kallas R, Li J, Goldman DW, Magder LS, Petri M (2022) Trajectory of damage accrual in Systemic Lupus Erythematosus based on ethnicity and socioeconomic factors. J Rheumatol 49(11):1229\u20131235. https:\/\/doi.org\/10.3899\/jrheum.211135","journal-title":"J Rheumatol"},{"key":"6187_CR13","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/ncomms3240","volume":"4","author":"S Vyas","year":"2013","unstructured":"Vyas S, Chesarone-Cataldo M, Todorova T, Huang YH, Chang P (2013) A systematic analysis of the PARP protein family identifies new functions critical for cell physiology. Nat Commun 4:2240. https:\/\/doi.org\/10.1038\/ncomms3240","journal-title":"Nat Commun"},{"issue":"1","key":"6187_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5426","volume":"5","author":"S Vyas","year":"2014","unstructured":"Vyas S et al (2014) Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat Commun 5(1):4426. https:\/\/doi.org\/10.1038\/ncomms5426","journal-title":"Nat Commun"},{"key":"6187_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010041","author":"S Pazzaglia","year":"2019","unstructured":"Pazzaglia S, Pioli C (2019) Multifaceted role of PARP-1 in DNA repair and inflammation: pathological and therapeutic implications in cancer and non-cancer diseases. Cells. https:\/\/doi.org\/10.3390\/cells9010041","journal-title":"Cells"},{"issue":"4","key":"6187_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/imm.12099","volume":"139","author":"MM Rosado","year":"2013","unstructured":"Rosado MM, Bennici E, Novelli F, Pioli C (2013) Beyond DNA repair, the immunological role of PARP-1 and its siblings. Immunology 139(4):428\u201337. https:\/\/doi.org\/10.1111\/imm.12099","journal-title":"Immunology"},{"key":"6187_CR17","doi-asserted-by":"crossref","unstructured":"D\u2019Amours D, Desnoyers S, D\u2019Silva I, Poirier GG (1999) Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions, (in eng), Biochem J, vol. 342 (Pt 2), no. Pt 2, pp. 249\u201368, Sep 1","DOI":"10.1042\/bj3420249"},{"issue":"46","key":"6187_CR18","doi-asserted-by":"publisher","first-page":"30069","DOI":"10.1074\/jbc.273.46.30069","volume":"273","author":"WM Shieh","year":"1998","unstructured":"Shieh WM et al (1998) Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J Biol Chem 273(46):30069\u201372. https:\/\/doi.org\/10.1074\/jbc.273.46.30069","journal-title":"J Biol Chem"},{"issue":"7","key":"6187_CR19","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1084\/jem.186.7.1041","volume":"186","author":"C Szab\u00f3","year":"1997","unstructured":"Szab\u00f3 C et al (1997) Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects. J Exp Med 186(7):1041\u20139. https:\/\/doi.org\/10.1084\/jem.186.7.1041","journal-title":"J Exp Med"},{"issue":"5579","key":"6187_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1126\/science.1072221","volume":"297","author":"SW Yu","year":"2002","unstructured":"Yu SW et al (2002) Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297(5579):259\u201363. https:\/\/doi.org\/10.1126\/science.1072221","journal-title":"Science"},{"key":"6187_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/837250","volume":"2015","author":"S Garc\u00eda","year":"2015","unstructured":"Garc\u00eda S, Conde C (2015) The role of Poly(ADP-ribose) Polymerase-1 in rheumatoid arthritis. Mediators Inflamm 2015:837250. https:\/\/doi.org\/10.1155\/2015\/837250","journal-title":"Mediators Inflamm"},{"issue":"4","key":"6187_CR22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2174\/187153011797881184","volume":"11","author":"F Laudisi","year":"2011","unstructured":"Laudisi F, Sambucci M, Pioli C (2011) Poly (ADP-ribose) polymerase-1 (PARP-1) as immune regulator. Endocr Metab Immune Disord Drug Targets 11(4):326\u201333. https:\/\/doi.org\/10.2174\/187153011797881184","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"7","key":"6187_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00296-008-0772-8","volume":"29","author":"I Onaran","year":"2009","unstructured":"Onaran I, Tezcan G, Ozg\u00f6nenel L, Cetin E, Ozdemir AT, Kanig\u00fcr-Sultuybek G (2009) The Val762Ala polymorphism in the poly(ADP-ribose) polymerase-1 gene is not associated with susceptibility in Turkish rheumatoid arthritis patients. Rheumatol Int 29(7):797\u2013800. https:\/\/doi.org\/10.1007\/s00296-008-0772-8","journal-title":"Rheumatol Int"},{"issue":"1","key":"6187_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00296-010-1589-9","volume":"32","author":"KA Lee","year":"2012","unstructured":"Lee KA, Bang SY, Park BL, Kim JH, Shin HD, Bae SC (2012) Lack of association between poly(ADP-ribose) polymerase (PARP) polymorphisms and rheumatoid arthritis in a Korean population. Rheumatol Int 32(1):91\u20136. https:\/\/doi.org\/10.1007\/s00296-010-1589-9","journal-title":"Rheumatol Int"},{"issue":"4","key":"6187_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/bf00301776","volume":"15","author":"W Ehrlich","year":"1995","unstructured":"Ehrlich W, Huser H, Kr\u00f6ger H (1995) Inhibition of the induction of collagenase by interleukin-1 ? in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobenzamide. Rheumatol Int 15(4):171\u2013172. https:\/\/doi.org\/10.1007\/bf00301776","journal-title":"Rheumatol Int"},{"issue":"9","key":"6187_CR26","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s00296-013-2711-6","volume":"33","author":"J Lee","year":"2013","unstructured":"Lee J et al (2013) CIP2A facilitates apoptotic resistance of fibroblast-like synoviocytes in rheumatoid arthritis independent of c-Myc expression. Rheumatol Int 33(9):2241\u20132248. https:\/\/doi.org\/10.1007\/s00296-013-2711-6","journal-title":"Rheumatol Int"},{"key":"6187_CR27","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"TJJPT Higgins","year":"2024","unstructured":"Higgins TJJPT, Chandler J, Cumpston M, Li T, Page MJ (2024) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane"},{"key":"6187_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https:\/\/doi.org\/10.1136\/bmj.n160","journal-title":"BMJ"},{"issue":"1","key":"6187_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.intimp.2014.01.005","volume":"19","author":"SF Ahmad","year":"2014","unstructured":"Ahmad SF, Attia SM, Zoheir KM, Ashour AE, Bakheet SA (2014) Attenuation of the progression of adjuvant-induced arthritis by 3-aminobenzamide treatment. Int Immunopharmacol 19(1):52\u20139. https:\/\/doi.org\/10.1016\/j.intimp.2014.01.005","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"6187_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cyto.2014.04.006","volume":"68","author":"SF Ahmad","year":"2014","unstructured":"Ahmad SF, Zoheir KM, Bakheet SA, Ashour AE, Attia SM (2014) Poly(ADP-ribose) polymerase-1 inhibitor modulates T regulatory and IL-17 cells in the prevention of adjuvant induced arthritis in mice model. Cytokine 68(2):76\u201385. https:\/\/doi.org\/10.1016\/j.cyto.2014.04.006","journal-title":"Cytokine"},{"issue":"1","key":"6187_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/096120339600500105","volume":"5","author":"HY Chen","year":"1996","unstructured":"Chen HY, Pertusi RM, Kirkland JB, Rubin BR, Jacobson EL (1996) Biochemical characterization of ADP-ribose polymer metabolism in SLE. Lupus 5(1):14\u201321. https:\/\/doi.org\/10.1177\/096120339600500105","journal-title":"Lupus"},{"issue":"7","key":"6187_CR32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/sj.gene.6364420","volume":"8","author":"EY Chung","year":"2007","unstructured":"Chung EY, Liu J, Zhang Y, Ma X (2007) Differential expression in Lupus-associated IL-10 promoter single-nucleotide polymorphisms is mediated by poly(ADP-ribose) polymerase-1. Genes Immun 8(7):577\u201389. https:\/\/doi.org\/10.1038\/sj.gene.6364420","journal-title":"Genes Immun"},{"issue":"5","key":"6187_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2007.077040","volume":"67","author":"S Garc\u00eda","year":"2008","unstructured":"Garc\u00eda S, Boda\u00f1o A, Pablos JL, G\u00f3mez-Reino JJ, Conde C (2008) Poly(ADP-ribose) polymerase inhibition reduces tumor necrosis factor-induced inflammatory response in rheumatoid synovial fibroblasts. Ann Rheum Dis 67(5):631\u20137. https:\/\/doi.org\/10.1136\/ard.2007.077040","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"6187_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001071","volume":"2","author":"E Gonzalez-Rey","year":"2007","unstructured":"Gonzalez-Rey E et al (2007) Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response. PLoS One 2(10):e1071. https:\/\/doi.org\/10.1371\/journal.pone.0001071","journal-title":"PLoS One"},{"issue":"11","key":"6187_CR35","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.4049\/jimmunol.0803565","volume":"182","author":"NR Jog","year":"2009","unstructured":"Jog NR, Dinnall JA, Gallucci S, Madaio MP, Caricchio R (2009) Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation. J Immunol 182(11):7297\u2013306. https:\/\/doi.org\/10.4049\/jimmunol.0803565","journal-title":"J Immunol"},{"issue":"1","key":"6187_CR36","doi-asserted-by":"publisher","first-page":"C82","DOI":"10.1152\/ajpcell.00486.2004","volume":"289","author":"T Kitamura","year":"2005","unstructured":"Kitamura T, Sekimata M, Kikuchi S, Homma Y (2005) Involvement of poly(ADP-ribose) polymerase 1 in ERBB2 expression in rheumatoid synovial cells. Am J Physiol Cell Physiol 289(1):C82-8. https:\/\/doi.org\/10.1152\/ajpcell.00486.2004","journal-title":"Am J Physiol Cell Physiol"},{"issue":"9","key":"6187_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006292","volume":"12","author":"G Li","year":"2016","unstructured":"Li G et al (2016) The Rheumatoid Arthritis risk variant CCR6DNP regulates CCR6 via PARP-1. PLoS Genet 12(9):e1006292. https:\/\/doi.org\/10.1371\/journal.pgen.1006292","journal-title":"PLoS Genet"},{"issue":"3","key":"6187_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/bf01534394","volume":"19","author":"R Miesel","year":"1995","unstructured":"Miesel R, Kurpisz M, Kr\u00f6ger H (1995) Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase. Inflammation 19(3):379\u201387. https:\/\/doi.org\/10.1007\/bf01534394","journal-title":"Inflammation"},{"key":"6187_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cbi.2019.04.015","volume":"306","author":"X Su","year":"2019","unstructured":"Su X et al (2019) MiR-199-3p promotes ERK-mediated IL-10 production by targeting poly (ADP-ribose) polymerase-1 in patients with systemic lupus erythematosus. Chem Biol Interact 306:110\u2013116. https:\/\/doi.org\/10.1016\/j.cbi.2019.04.015","journal-title":"Chem Biol Interact"},{"issue":"5","key":"6187_CR40","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/annrheumdis-2017-212265","volume":"77","author":"Y Zhang","year":"2018","unstructured":"Zhang Y et al (2018) Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. Ann Rheum Dis 77(5):744\u2013751. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212265","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6187_CR41","doi-asserted-by":"publisher","first-page":"R14","DOI":"10.1186\/ar1865","volume":"8","author":"S Garc\u00eda","year":"2006","unstructured":"Garc\u00eda S, Boda\u00f1o A, Gonz\u00e1lez A, Forteza J, G\u00f3mez-Reino JJ, Conde C (2006) Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice. Arthritis Res Ther 8(1):R14. https:\/\/doi.org\/10.1186\/ar1865","journal-title":"Arthritis Res Ther"},{"issue":"4\u20136","key":"6187_CR42","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/15257771003741471","volume":"29","author":"B Cerboni","year":"2010","unstructured":"Cerboni B, Di Stefano A, Micheli V, Morozzi G, Pompucci G, Sestini S (2010) PARP activity and NAD concentration in PMC from patients affected by systemic sclerosis and lupus erythematosus. Nucleosides Nucleotides Nucleic Acids 29(4\u20136):471\u20135. https:\/\/doi.org\/10.1080\/15257771003741471","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"7","key":"6187_CR43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.humimm.2009.04.021","volume":"70","author":"B Cerboni","year":"2009","unstructured":"Cerboni B et al (2009) Poly(ADP-ribose) polymerase activity in systemic lupus erythematosus and systemic sclerosis. Hum Immunol 70(7):487\u201391. https:\/\/doi.org\/10.1016\/j.humimm.2009.04.021","journal-title":"Hum Immunol"},{"issue":"10","key":"6187_CR44","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1002\/1529-0131(199910)42:10<2194::AID-ANR22>3.0.CO;2-U","volume":"42","author":"O Delrieu","year":"1999","unstructured":"Delrieu O et al (1999) Poly(ADP-ribose) polymerase alleles in French Caucasians are associated neither with lupus nor with primary antiphospholipid syndrome. Arthr Rhuem 42(10):2194\u20132197. https:\/\/doi.org\/10.1002\/1529-0131(199910)42:10%3C2194::AID-ANR22%3E3.0.CO;2-U. \/10\/01 1999, doi","journal-title":"Arthr Rhuem"},{"issue":"6","key":"6187_CR45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/13547500902987033","volume":"14","author":"MR Faraone-Mennella","year":"2009","unstructured":"Faraone-Mennella MR, Scarpa R, Petrella A, Manguso F, Peluso R, Farina B (2009) Detecting clinical activity in systemic lupus erythematosus with an archaeal poly(ADP-ribose) polymerase-like thermozyme: a pivotal study. Biomarkers 14(6):381\u20137. https:\/\/doi.org\/10.1080\/13547500902987033","journal-title":"Biomarkers"},{"issue":"6","key":"6187_CR46","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/rheumatology\/kei262","volume":"45","author":"JW Hur","year":"2006","unstructured":"Hur JW, Sung YK, Shin HD, Park BL, Cheong HS, Bae SC (2006) Poly(ADP-ribose) polymerase (PARP) polymorphisms associated with nephritis and arthritis in systemic lupus erythematosus. Rheumatology (Oxford) 45(6):711\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kei262","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"6187_CR47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jaut.2003.10.009","volume":"22","author":"D Jeoung","year":"2004","unstructured":"Jeoung D et al (2004) Identification of autoantibody against poly (ADP-ribose) polymerase (PARP) fragment as a serological marker in systemic lupus erythematosus. J Autoimmun 22(1):87\u201394. https:\/\/doi.org\/10.1016\/j.jaut.2003.10.009","journal-title":"J Autoimmun"},{"issue":"2","key":"6187_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/096120339400300210","volume":"3","author":"JS Lee","year":"1994","unstructured":"Lee JS, Haug BL, Sibley JT (1994) Decreased mRNA levels coding for poly(ADP-ribose) polymerase in lymphocytes of patients with SLE. Lupus 3(2):113\u20136. https:\/\/doi.org\/10.1177\/096120339400300210","journal-title":"Lupus"},{"issue":"1","key":"6187_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s0006-291x(02)00637-x","volume":"295","author":"Y Lim","year":"2002","unstructured":"Lim Y et al (2002) Identification of autoantibodies associated with systemic lupus erythematosus. Biochem Biophys Res Commun 295(1):119\u201324. https:\/\/doi.org\/10.1016\/s0006-291x(02)00637-x","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"6187_CR50","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/rheumatology\/kez634","volume":"59","author":"HZ Ling","year":"2020","unstructured":"Ling HZ et al (2020) Discovery of new serum biomarker panels for systemic lupus erythematosus diagnosis. Rheumatology (Oxford) 59(6):1416\u20131425. https:\/\/doi.org\/10.1093\/rheumatology\/kez634","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"6187_CR51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3109\/08916939009041040","volume":"6","author":"C Negri","year":"1990","unstructured":"Negri C et al (1990) Autoantibodies to poly(ADP-ribose)polymerase in autoimmune diseases. Autoimmunity 6(3):203\u20139. https:\/\/doi.org\/10.3109\/08916939009041040","journal-title":"Autoimmunity"},{"issue":"7","key":"6187_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114379","volume":"43","author":"W Pan","year":"2024","unstructured":"Pan W, Tsokos MG, Scherlinger M, Li W, Tsokos GC (2024) The PP2A regulatory subunit PPP2R2A controls NAD(+) biosynthesis to regulate T cell subset differentiation in systemic autoimmunity. Cell Rep 43(7):114379. https:\/\/doi.org\/10.1016\/j.celrep.2024.114379","journal-title":"Cell Rep"},{"issue":"1","key":"6187_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0022-1759(89)90315-3","volume":"116","author":"S Prasad","year":"1989","unstructured":"Prasad S, Thraves P, Kanai Y, Smulson M, Dritschilo A (1989) A dot-blot method for screening polyclonal and monoclonal antisera to poly(ADP-ribose). J Immunol Methods 116(1):79\u201385. https:\/\/doi.org\/10.1016\/0022-1759(89)90315-3","journal-title":"J Immunol Methods"},{"issue":"8","key":"6187_CR54","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1172\/jci5967","volume":"103","author":"BP Tsao","year":"1999","unstructured":"Tsao BP et al (1999) PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus. J Clin Invest 103(8):1135\u201340. https:\/\/doi.org\/10.1172\/jci5967","journal-title":"J Clin Invest"},{"issue":"2","key":"6187_CR55","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1006\/clin.1994.1187","volume":"73","author":"S Muller","year":"1994","unstructured":"Muller S et al (1994) Autoantibodies reacting with poly(ADP-ribose) and with a zinc-finger functional domain of poly(ADP-ribose) polymerase involved in the recognition of damaged DNA. Clin Immunol Immunopathol 73(2):187\u201396. https:\/\/doi.org\/10.1006\/clin.1994.1187","journal-title":"Clin Immunol Immunopathol"},{"key":"6187_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2025.503881","volume":"906","author":"MSM Attia","year":"2025","unstructured":"Attia MSM et al (2025) The PPAR-\u03b2\/\u03b4 agonist GW0742 alleviates DNA damage and lupus nephritis in an animal model of systemic lupus erythematosus via restoring DNA repair gene expression. Mutat Res Genet Toxicol Environ Mutagen 906:503881. https:\/\/doi.org\/10.1016\/j.mrgentox.2025.503881","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"6187_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-12-36","volume":"12","author":"M Emonts","year":"2011","unstructured":"Emonts M et al (2011) Polymorphisms in genes controlling inflammation and tissue repair in Rheumatoid Arthritis: a case control study. BMC Med Genet 12:36. https:\/\/doi.org\/10.1186\/1471-2350-12-36","journal-title":"BMC Med Genet"},{"issue":"6","key":"6187_CR58","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s10528-024-10989-x","volume":"63","author":"Y Fang","year":"2025","unstructured":"Fang Y, Xu N, Shen J, Chen H, Li G (2025) Exploration of the regulatory network of programmed cell death genes in Rheumatoid Arthritis based on blood-derived circRNA transcriptome information and single-cell multi-omics data. Biochem Genet 63(6):5361\u20135382. https:\/\/doi.org\/10.1007\/s10528-024-10989-x","journal-title":"Biochem Genet"},{"key":"6187_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030714","author":"J Panezai","year":"2022","unstructured":"Panezai J et al (2022) Periodontal disease augments cardiovascular disease risk biomarkers in Rheumatoid Arthritis. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10030714","journal-title":"Biomedicines"},{"issue":"3","key":"6187_CR60","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/art.10864","volume":"48","author":"M Pascual","year":"2003","unstructured":"Pascual M et al (2003) A poly(ADP-ribose) polymerase haplotype spanning the promoter region confers susceptibility to rheumatoid arthritis. Arthritis Rheum 48(3):638\u201341. https:\/\/doi.org\/10.1002\/art.10864","journal-title":"Arthritis Rheum"},{"key":"6187_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2026.178547","volume":"1015","author":"Y Zhang","year":"2026","unstructured":"Zhang Y et al (2026) The anoikis signature in rheumatoid arthritis: insights into methotrexate resistance and the complementary therapeutic role of triptolide. Eur J Pharmacol 1015:178547. https:\/\/doi.org\/10.1016\/j.ejphar.2026.178547","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"6187_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-06656-9","volume":"15","author":"MZ Hussain","year":"2025","unstructured":"Hussain MZ et al (2025) Association of DNA damage response pathway genes with rheumatoid arthritis risks: a case-control study. Sci Rep 15(1):20937. https:\/\/doi.org\/10.1038\/s41598-025-06656-9","journal-title":"Sci Rep"},{"key":"6187_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.582401","volume":"11","author":"NI Vlachogiannis","year":"2020","unstructured":"Vlachogiannis NI et al (2020) Association between DNA damage response, fibrosis and Type I Interferon signature in Systemic Sclerosis. Front Immunol 11:582401. https:\/\/doi.org\/10.3389\/fimmu.2020.582401","journal-title":"Front Immunol"},{"key":"6187_CR64","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20160336","author":"M Honarpisheh","year":"2016","unstructured":"Honarpisheh M et al (2016) Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis. Biosci Rep. https:\/\/doi.org\/10.1042\/bsr20160336","journal-title":"Biosci Rep"},{"issue":"5","key":"6187_CR65","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40620-018-0482-6","volume":"31","author":"A Milillo","year":"2018","unstructured":"Milillo A et al (2018) Defective activation of the MAPK\/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Sch\u00f6nlein purpura. J Nephrol 31(5):731\u2013741. https:\/\/doi.org\/10.1007\/s40620-018-0482-6","journal-title":"J Nephrol"},{"issue":"3","key":"6187_CR66","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1172\/jci113150","volume":"80","author":"H Yamanaka","year":"1987","unstructured":"Yamanaka H, Willis EH, Penning CA, Peebles CL, Tan EM, Carson DA (1987) Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase. J Clin Invest 80(3):900\u20134. https:\/\/doi.org\/10.1172\/jci113150","journal-title":"J Clin Invest"},{"issue":"11","key":"6187_CR67","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1021\/acs.jproteome.5c00645","volume":"24","author":"Q Zhang","year":"2025","unstructured":"Zhang Q et al (2025) Molecular signatures of nuclear protein alterations in Systemic Lupus Erythematosus across disease stages. J Proteome Res 24(11):5780\u20135792. https:\/\/doi.org\/10.1021\/acs.jproteome.5c00645","journal-title":"J Proteome Res"},{"issue":"3","key":"6187_CR68","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2217\/bmm.16.3","volume":"10","author":"AR Bianchi","year":"2016","unstructured":"Bianchi AR et al (2016) Automodification of PARP and fatty acid-based membrane lipidome as a promising integrated biomarker panel in molecular medicine. Biomark Med 10(3):229\u201342. https:\/\/doi.org\/10.2217\/bmm.16.3","journal-title":"Biomark Med"},{"issue":"6","key":"6187_CR69","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00393-006-0045-4","volume":"65","author":"I B\u00f6hm","year":"2006","unstructured":"B\u00f6hm I (2006) [The apoptosis marker enzyme poly-(ADP-ribose) polymerase (PARP) in Systemic Lupus Erythematosus]. Z Rheumatol 65(6):541\u20134. https:\/\/doi.org\/10.1007\/s00393-006-0045-4","journal-title":"Z Rheumatol"},{"issue":"3","key":"6187_CR70","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/0891693031000105617","volume":"36","author":"I B\u00f6hm","year":"2003","unstructured":"B\u00f6hm I (2003) Disruption of the cytoskeleton after apoptosis induction with autoantibodies. Autoimmunity 36(3):183\u20139. https:\/\/doi.org\/10.1080\/0891693031000105617","journal-title":"Autoimmunity"},{"issue":"6","key":"6187_CR71","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/03009740410006907","volume":"33","author":"I B\u00f6hm","year":"2004","unstructured":"B\u00f6hm I (2004) Apoptosis: the link between autoantibodies and leuko-\/lymphocytopenia in patients with lupus erythematosus. Scand J Rheumatol 33(6):409\u201316. https:\/\/doi.org\/10.1080\/03009740410006907","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"6187_CR72","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11926-001-0018-1","volume":"3","author":"JS Navratil","year":"2001","unstructured":"Navratil JS, Ahearn JM (2001) Apoptosis, clearance mechanisms, and the development of systemic lupus erythematosus. Curr Rheumatol Rep 3(3):191\u20138. https:\/\/doi.org\/10.1007\/s11926-001-0018-1","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"6187_CR73","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/154411130401500304","volume":"15","author":"A Rosen","year":"2004","unstructured":"Rosen A, Casciola-Rosen L (2004) Altered autoantigen structure in Sj\u00f6gren\u2019s syndrome: implications for the pathogenesis of autoimmune tissue damage. Crit Rev Oral Biol Med 15(3):156\u201364. https:\/\/doi.org\/10.1177\/154411130401500304","journal-title":"Crit Rev Oral Biol Med"},{"issue":"5673","key":"6187_CR74","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/274809a0","volume":"274","author":"Y Kanai","year":"1978","unstructured":"Kanai Y, Sugimura T, Matsushima T (1978) Induction of specific antibodies to poly(ADP-ribose) in rabbits by double-stranded RNA, poly(A)-poly(U). Nature 274(5673):809\u201312. https:\/\/doi.org\/10.1038\/274809a0","journal-title":"Nature"},{"issue":"7","key":"6187_CR75","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc3748","volume":"14","author":"S Vyas","year":"2014","unstructured":"Vyas S, Chang P (2014) New PARP targets for cancer therapy. Nat Rev Cancer 14(7):502\u20139. https:\/\/doi.org\/10.1038\/nrc3748","journal-title":"Nat Rev Cancer"},{"key":"6187_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00301","volume":"3","author":"JD Steffen","year":"2013","unstructured":"Steffen JD, Brody JR, Armen RS, Pascal JM (2013) Structural implications for selective targeting of PARPs. Front Oncol 3:301. https:\/\/doi.org\/10.3389\/fonc.2013.00301","journal-title":"Front Oncol"},{"issue":"1","key":"6187_CR77","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/anie.201609655","volume":"56","author":"B Peng","year":"2017","unstructured":"Peng B, Thorsell AG, Karlberg T, Sch\u00fcler H, Yao SQ (2017) Small molecule microarray based discovery of PARP14 inhibitors. Angew Chem Int Ed Engl 56(1):248\u2013253. https:\/\/doi.org\/10.1002\/anie.201609655","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"6187_CR78","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bmcl.2015.12.018","volume":"26","author":"T Haikarainen","year":"2016","unstructured":"Haikarainen T et al (2016) Development and structural analysis of adenosine site binding tankyrase inhibitors. Bioorg Med Chem Lett 26(2):328\u2013333. https:\/\/doi.org\/10.1016\/j.bmcl.2015.12.018","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"6187_CR79","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1021\/jm301607v","volume":"56","author":"H Bregman","year":"2013","unstructured":"Bregman H et al (2013) Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. J Med Chem 56(3):1341\u20135. https:\/\/doi.org\/10.1021\/jm301607v","journal-title":"J Med Chem"},{"issue":"46","key":"6187_CR80","doi-asserted-by":"publisher","first-page":"13898","DOI":"10.1039\/d2sc04820e","volume":"13","author":"DS Bejan","year":"2022","unstructured":"Bejan DS et al (2022) Structure-guided design and characterization of a clickable, covalent PARP16 inhibitor. Chem Sci 13(46):13898\u201313906. https:\/\/doi.org\/10.1039\/d2sc04820e","journal-title":"Chem Sci"},{"issue":"3","key":"6187_CR81","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216235","volume":"15","author":"LM Wang","year":"2023","unstructured":"Wang LM et al (2023) Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance. EMBO Mol Med 15(3):e16235. https:\/\/doi.org\/10.15252\/emmm.202216235","journal-title":"EMBO Mol Med"},{"issue":"3","key":"6187_CR82","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/nar\/gks1337","volume":"41","author":"L MacPherson","year":"2013","unstructured":"MacPherson L, Tamblyn L, Rajendra S, Bralha F, McPherson JP, Matthews J (2013) 2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation. Nucleic Acids Res 41(3):1604\u201321. https:\/\/doi.org\/10.1093\/nar\/gks1337","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"6187_CR83","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1177\/09612033251367586","volume":"34","author":"A Sohanforooshan Moghaddam","year":"2025","unstructured":"Sohanforooshan Moghaddam A, Salehi M, Esmaeilzadeh E, Mosallaei M (2025) Diagnostic and clinical implications of PARP9 promoter methylation in systemic lupus erythematosus and rheumatoid arthritis. Lupus 34(12):1230\u20131239. https:\/\/doi.org\/10.1177\/09612033251367586","journal-title":"Lupus"},{"issue":"1","key":"6187_CR84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1349-7006.2003.tb01344.x","volume":"94","author":"M Kuwano","year":"2003","unstructured":"Kuwano M et al (2003) The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 94(1):9\u201314. https:\/\/doi.org\/10.1111\/j.1349-7006.2003.tb01344.x","journal-title":"Cancer Sci"},{"key":"6187_CR85","unstructured":"Leonard GD, Polgar O, Bates SE (2002) ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 3: (1)1652\u20139"},{"issue":"1","key":"6187_CR86","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s0966-842x(02)00010-0","volume":"11","author":"KS McKeegan","year":"2003","unstructured":"McKeegan KS, Borges-Walmsley MI, Walmsley AR (2003) The structure and function of drug pumps: an update. Trends Microbiol 11(1):21\u20139. https:\/\/doi.org\/10.1016\/s0966-842x(02)00010-0","journal-title":"Trends Microbiol"},{"issue":"5","key":"6187_CR87","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2177\/jsci.29.319","volume":"29","author":"Y Tanaka","year":"2006","unstructured":"Tanaka Y, Tsujimura S (2006) [Multi-drug resistance in the treatments of autoimmune diseases]. Nihon Rinsho Meneki Gakkai Kaishi 29(5):319\u201324. https:\/\/doi.org\/10.2177\/jsci.29.319","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"issue":"6","key":"6187_CR88","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/03009740310004333","volume":"32","author":"G Jansen","year":"2003","unstructured":"Jansen G, Scheper RJ, Dijkmans BA (2003) Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview. Scand J Rheumatol 32(6):325\u201336. https:\/\/doi.org\/10.1080\/03009740310004333","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"6187_CR89","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1271\/bbb.100816","volume":"75","author":"K Ueda","year":"2011","unstructured":"Ueda K (2011) ABC proteins protect the human body and maintain optimal health. Biosci Biotechnol Biochem 75(3):401\u20139. https:\/\/doi.org\/10.1271\/bbb.100816","journal-title":"Biosci Biotechnol Biochem"},{"key":"6187_CR90","unstructured":"Llorente L et al (2000) Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine. 67:(1)30\u20139"},{"key":"6187_CR91","doi-asserted-by":"crossref","unstructured":"List AF et al (2002) Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood 100:(5)1910\u20132","DOI":"10.1182\/blood.V100.5.1910.h81702001910_1910_1912"},{"issue":"2\u20133","key":"6187_CR92","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ejphar.2007.11.067","volume":"583","author":"CM Pariante","year":"2008","unstructured":"Pariante CM (2008) The role of multi-drug resistance P-glycoprotein in glucocorticoid function: studies in animals and relevance in humans. Eur J Pharmacol 583(2\u20133):263\u201371. https:\/\/doi.org\/10.1016\/j.ejphar.2007.11.067","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"6187_CR93","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/art.24354","volume":"60","author":"JW Heijden","year":"2009","unstructured":"van der Heijden JW et al (2009) Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to Methotrexate and Leflunomide. Arthritis Rheum 60(3):669\u201377. https:\/\/doi.org\/10.1002\/art.24354","journal-title":"Arthritis Rheum"},{"issue":"6","key":"6187_CR94","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/art.21032","volume":"52","author":"S Tsujimura","year":"2005","unstructured":"Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y (2005) Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with Systemic Lupus Erythematosus. Arthritis Rheum 52(6):1676\u201383. https:\/\/doi.org\/10.1002\/art.21032","journal-title":"Arthritis Rheum"},{"key":"6187_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114542","volume":"239","author":"K Engle","year":"2022","unstructured":"Engle K, Kumar G (2022) Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update. Eur J Med Chem 239:114542. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114542","journal-title":"Eur J Med Chem"},{"issue":"6","key":"6187_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189221","volume":"1879","author":"R Bi","year":"2024","unstructured":"Bi R et al (2024) Emerging strategies to overcome PARP inhibitors\u2019 resistance in ovarian cancer. Biochim Biophys Acta Rev Cancer 1879(6):189221. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189221","journal-title":"Biochim Biophys Acta Rev Cancer"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06187-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06187-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06187-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:39:16Z","timestamp":1783525156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06187-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":96,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["6187"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06187-0","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No part of this review is copied, published elsewhere (in whole or in part), or generated by AI.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Artificial intelligence was not used in the drafting or editing of this manuscript. AI was used to assist in building the code used to produce Figure 2 using Python.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical AI use"}}],"article-number":"138"}}